What is colorectal cancer (CRC)?

- 3rd most common cancer worldwide
- High survival rate when diagnosed at early stage

85-90% of CRC develops from adenomas
- Early detection and removal of precancerous adenomas lowers CRC incidence rate

Current tests are limited

<table>
<thead>
<tr>
<th>Method</th>
<th>Invasive</th>
<th>Compliance</th>
<th>Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colonoscopy</td>
<td>Yes</td>
<td>Low</td>
<td>High</td>
</tr>
<tr>
<td>Stool-based</td>
<td>No</td>
<td>Low</td>
<td>Low</td>
</tr>
<tr>
<td>Blood-based</td>
<td>No</td>
<td>High</td>
<td>Low</td>
</tr>
</tbody>
</table>

ColonES - Fast, Efficient and Scalable

- Plasma-based assay using as little as 10 ng of circulating tumor methylated DNA (ctmDNA)
- Interrogates >20k methylation sites in >600 regions of interest
- Highly efficient targeted sequencing library construction
- Specialized analysis that reduces noise and increases accuracy
# Assay Workflow

1. **Blood Draw**
2. **Plasma Separation**
3. **DNA Extraction**
4. **ColonES Assay** (1 day workflow)
5. **Sequencing**
6. **Proprietary Analysis**

# Results from 1,283 Healthy and Affected Samples

## Performance of ColonES

- High AUC for both CRC and advanced adenomas.
- High sensitivity even in early stage CRC and adenomas.

## Covariate Analysis

- High sensitivity regardless of tumor size, tumor location, subject age, or subject sex.

### ColonES Sensitivity

- **Stage II-IV cancer patients**: 94%
- **Stage I cancer patients**: 97%
- **Adenoma patients**: 91%

### ColonES Specificity

- **Healthy participants**: 99%